| 22.28 -0.52 (-2.28%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.14 | 1-year : | 32.87 |
| Resists | First : | 24.1 | Second : | 28.14 |
| Pivot price | 22.54 |
|||
| Supports | First : | 21.1 | Second : | 19.26 |
| MAs | MA(5) : | 22.11  |
MA(20) : | 22.49 |
| MA(100) : | 23.2 |
MA(250) : | 22.24 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 40.2 |
D(3) : | 32.2 |
| RSI | RSI(14): 47.7 |
|||
| 52-week | High : | 30.47 | Low : | 16.1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ APLS ] has closed above bottom band by 37.3%. Bollinger Bands are 65.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 22.83 - 22.97 | 22.97 - 23.08 |
| Low: | 21.78 - 21.92 | 21.92 - 22.05 |
| Close: | 22.08 - 22.3 | 22.3 - 22.51 |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Sat, 21 Feb 2026
RTW INVESTMENTS, LP Acquires Significant Stake in Apellis Pharma - GuruFocus
Thu, 19 Feb 2026
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting - Yahoo Finance
Wed, 18 Feb 2026
Readystate Asset Management LP Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Tue, 17 Feb 2026
Earnings Preview: Apellis Pharmaceuticals, Inc. (APLS) Q4 Earnings Expected to Decline - Yahoo Finance
Tue, 17 Feb 2026
Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Tuesday - MarketBeat
Wed, 11 Feb 2026
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Savant Capital LLC - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 127 (M) |
| Shares Float | 89 (M) |
| Held by Insiders | 13.6 (%) |
| Held by Institutions | 102.4 (%) |
| Shares Short | 18,110 (K) |
| Shares Short P.Month | 17,250 (K) |
| EPS | 0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.17 |
| Profit Margin | 4.4 % |
| Operating Margin | 48.6 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | 14.1 % |
| Qtrly Rev. Growth | 133 % |
| Gross Profit (p.s.) | 4.78 |
| Sales Per Share | 8.06 |
| EBITDA (p.s.) | 0.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 79 (M) |
| Levered Free Cash Flow | 49 (M) |
| PE Ratio | 63.65 |
| PEG Ratio | 0 |
| Price to Book value | 7.02 |
| Price to Sales | 2.76 |
| Price to Cash Flow | 35.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|